Vanta Bioscience, a company in the Healthcare Research, Analytics & Technology industry, reported revenue of ₹1.06 crore and net profit of ₹0.05 crore for the September 2026 quarter.
Vanta Bioscience (BSE: VANTABIO) closed at ₹18.00 on 17 Nov 2026, down 31.4% over the past year. Its market capitalisation is ₹13 crore and it trades at 116.4 times earnings.
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.